NASDAQ:SNSS - Sunesis Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.71 -0.06 (-2.17 %)
(As of 05/21/2018 04:00 PM ET)
Previous Close$2.76
Today's Range$2.66 - $2.76
52-Week Range$1.82 - $7.69
Volume3,111 shs
Average Volume238,261 shs
Market Capitalization$95.21 million
P/E Ratio-1.88
Dividend YieldN/A
Beta1.79

About Sunesis Pharmaceuticals (NASDAQ:SNSS)

Sunesis Pharmaceuticals logoSunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company also engages in developing TAK-580, a pan-Raf inhibitor program in combination with various anticancer agents for the treatment of advanced solid tumor cancers in adult patients; SNS-510, which is in preclinical pharmacology and toxicology studies for the treatment of solid tumor and hematologic malignancies; and vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). In addition, it is developing vosaroxin, which is in Phase 2 trial with decitabine for treatment of diagnosed acute AML or myelodysplastic syndrome (MDS); Phase 1/2 trial with azacitidine for treatment of MDS; Phase 2 trial with infusional cytarabine for treatment of AML; Phase 1/2 trial in adult patients with previously treated intermediate-2 or high-risk MDS; and Phase 1/2 trial with cytarabine tested as consolidation therapy. The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Receive SNSS News and Ratings via Email

Sign-up to receive the latest news and ratings for SNSS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SNSS
CUSIP86732860
Phone650-266-3500

Debt

Debt-to-Equity RatioN/A
Current Ratio2.31
Quick Ratio2.31

Price-To-Earnings

Trailing P/E Ratio-1.88
Forward P/E Ratio-2.79
P/E GrowthN/A

Sales & Book Value

Annual Sales$670,000.00
Price / Sales139.02
Cash FlowN/A
Price / CashN/A
Book Value$0.02 per share
Price / Book135.50

Profitability

EPS (Most Recent Fiscal Year)($1.45)
Net Income$-35,450,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-129.91%

Miscellaneous

Employees34
Outstanding Shares34,370,000

Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions

What is Sunesis Pharmaceuticals' stock symbol?

Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."

How were Sunesis Pharmaceuticals' earnings last quarter?

Sunesis Pharmaceuticals (NASDAQ:SNSS) released its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.27) by $0.06. The biopharmaceutical company had revenue of $0.24 million for the quarter. View Sunesis Pharmaceuticals' Earnings History.

What price target have analysts set for SNSS?

5 brokerages have issued 12 month price objectives for Sunesis Pharmaceuticals' shares. Their forecasts range from $2.48 to $7.00. On average, they expect Sunesis Pharmaceuticals' share price to reach $4.4933 in the next year. View Analyst Ratings for Sunesis Pharmaceuticals.

What are Wall Street analysts saying about Sunesis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (5/10/2018)
  • 2. Cantor Fitzgerald analysts commented, "SNS-062 Data Now 3Q18. SNSS disclosed that it now expects to complete the Phase Ib trial of SNS-062 in fall 2018, which we interpret as early 4Q18, though it could be late 3Q18. The second dose cohort (50 mg) has not yet completed, but since a Phase Ia in healthy volunteers was run, our expectation has been that it would not take many doses to identify the Phase II dose (RP2D). While the reasons for the delay (rapidly progressing patient, non-drug related AE) are understandable, we think the disclosure could cause the shares to pull back." (3/8/2018)
  • 3. Cowen Inc analysts commented, "Sunesis reported Q3 Net loss of $9.9MM and pro forma September 30 cash of." (11/2/2017)

Who are some of Sunesis Pharmaceuticals' key competitors?

Who are Sunesis Pharmaceuticals' key executives?

Sunesis Pharmaceuticals' management team includes the folowing people:
  • Mr. Dayton Misfeldt, Interim CEO & Director (Age 44)
  • Mr. Daniel N. Swisher Jr., Strategic Advisor (Age 55)
  • Mr. William P. Quinn, CFO and Sr. VP of Fin. & Corp. Devel.
  • Mr. Gene C. Jamieson, VP of Technical Operations
  • Dr. Judith A. Fox Ph.D., Chief Scientific Officer

Has Sunesis Pharmaceuticals been receiving favorable news coverage?

Media stories about SNSS stock have trended somewhat positive this week, according to Accern. Accern ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sunesis Pharmaceuticals earned a news sentiment score of 0.09 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 47.37 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Sunesis Pharmaceuticals' major shareholders?

Sunesis Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (4.90%), DAFNA Capital Management LLC (1.09%), Millennium Management LLC (0.31%), Spark Investment Management LLC (0.22%) and Wells Fargo & Company MN (0.19%). Company insiders that own Sunesis Pharmaceuticals stock include Dayton Misfeldt, Geoffrey M Parker and Mpm Oncology Impact Management. View Institutional Ownership Trends for Sunesis Pharmaceuticals.

Which institutional investors are selling Sunesis Pharmaceuticals stock?

SNSS stock was sold by a variety of institutional investors in the last quarter, including DAFNA Capital Management LLC and BVF Inc. IL. View Insider Buying and Selling for Sunesis Pharmaceuticals.

Which institutional investors are buying Sunesis Pharmaceuticals stock?

SNSS stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Spark Investment Management LLC and Wells Fargo & Company MN. Company insiders that have bought Sunesis Pharmaceuticals stock in the last two years include Dayton Misfeldt, Geoffrey M Parker and Mpm Oncology Impact Management. View Insider Buying and Selling for Sunesis Pharmaceuticals.

How do I buy shares of Sunesis Pharmaceuticals?

Shares of SNSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sunesis Pharmaceuticals' stock price today?

One share of SNSS stock can currently be purchased for approximately $2.71.

How big of a company is Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals has a market capitalization of $95.21 million and generates $670,000.00 in revenue each year. The biopharmaceutical company earns $-35,450,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Sunesis Pharmaceuticals employs 34 workers across the globe.

How can I contact Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals' mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-3500 or via email at [email protected]


MarketBeat Community Rating for Sunesis Pharmaceuticals (SNSS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  259 (Vote Outperform)
Underperform Votes:  286 (Vote Underperform)
Total Votes:  545
MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNSS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNSS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sunesis Pharmaceuticals (NASDAQ:SNSS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Sunesis Pharmaceuticals in the last 12 months. Their average twelve-month price target is $4.4933, suggesting that the stock has a possible upside of 65.81%. The high price target for SNSS is $7.00 and the low price target for SNSS is $2.48. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.602.602.602.50
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.4933$4.4933$4.16$5.00
Price Target Upside: 65.81% upside38.95% downside24.55% upside63.99% upside

Sunesis Pharmaceuticals (NASDAQ:SNSS) Consensus Price Target History

Price Target History for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Sunesis Pharmaceuticals (NASDAQ:SNSS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2018CowenReiterated RatingHoldHighView Rating Details
3/8/2018Cantor FitzgeraldReiterated RatingHold$4.00HighView Rating Details
12/14/2017OppenheimerInitiated CoverageBuy$7.00LowView Rating Details
12/11/2017Wells FargoUpgradeMarket Perform ➝ Outperform$2.86 ➝ $2.48HighView Rating Details
11/20/2017UBSInitiated CoverageOutperformN/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Sunesis Pharmaceuticals (NASDAQ:SNSS) Earnings History and Estimates Chart

Earnings by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Sunesis Pharmaceuticals (NASDAQ:SNSS) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181($0.26)($0.26)($0.26)
Q3 20181($0.24)($0.24)($0.24)
Q4 20181($0.23)($0.23)($0.23)

Sunesis Pharmaceuticals (NASDAQ SNSS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.2670)($0.21)$0.24 millionViewN/AView Earnings Details
3/8/2018Q4 2017($0.29)($0.21)ViewListenView Earnings Details
11/2/2017Q3 2017($0.37)($0.43)$0.37 millionViewN/AView Earnings Details
7/27/2017Q2 2017($0.76)($0.41)$2.40 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.83)($0.47)$1.57 million$0.67 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.43)($0.44)$0.60 million$0.68 millionViewListenView Earnings Details
11/3/2016Q316($0.71)($0.62)$0.60 million$0.60 millionViewN/AView Earnings Details
7/29/2016Q216($0.10)($0.12)$0.70 million$0.60 millionViewListenView Earnings Details
5/5/2016Q116($0.12)($0.12)$0.77 million$0.64 millionViewListenView Earnings Details
3/10/2016Q415($0.14)($0.15)$0.84 million$0.67 millionViewListenView Earnings Details
11/5/2015Q315($0.12)($0.09)$1.09 million$0.68 millionViewListenView Earnings Details
7/30/2015Q215($0.13)($0.15)$1.21 million$0.85 millionViewN/AView Earnings Details
5/5/2015Q115($0.16)($0.13)$1.14 million$0.90 millionViewListenView Earnings Details
3/12/2015Q414($0.20)($0.02)$1.17 million$0.90 millionViewListenView Earnings Details
11/10/2014Q314($0.17)($0.25)$1.97 million$0.85 millionViewListenView Earnings Details
8/5/2014Q214($0.17)($0.20)$1.32 million$2.00 millionViewListenView Earnings Details
5/7/2014Q114($0.17)($0.26)$1.32 million$2.00 millionViewListenView Earnings Details
3/6/2014Q413($0.20)($0.15)$1.37 million$2.00 millionViewListenView Earnings Details
11/12/2013Q313($0.20)($0.16)$1.44 million$1.99 millionViewListenView Earnings Details
7/29/2013Q2 2013($0.21)$0.18$1.22 million$1.99 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.20)($0.23)$0.75 million$1.99 millionViewListenView Earnings Details
3/13/2013Q4 2012($0.19)($0.20)$0.32 million$1.99 millionViewListenView Earnings Details
11/8/2012Q312($0.11)($0.37)$4.17 million$0.26 millionViewN/AView Earnings Details
8/9/2012($0.20)($0.20)ViewN/AView Earnings Details
5/15/2012($0.18)($0.30)ViewN/AView Earnings Details
3/14/2012Q4 2011($1.14)($1.14)ViewN/AView Earnings Details
11/14/2011($0.18)($0.11)ViewN/AView Earnings Details
8/11/2011($0.15)($0.18)ViewN/AView Earnings Details
5/12/2011Q1 2011($0.84)($0.23)ViewN/AView Earnings Details
3/29/2011Q4 2010($0.60)($1.38)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.72)($0.83)ViewN/AView Earnings Details
8/12/2010Q2 2010($1.44)($2.63)ViewN/AView Earnings Details
4/29/2010Q1 2010($4.32)($3.89)ViewN/AView Earnings Details
3/30/2010Q4 2009($5.76)($5.40)ViewN/AView Earnings Details
11/16/2009Q3 2009($5.04)($5.11)ViewN/AView Earnings Details
7/29/2009Q2 2009($5.76)($29.54)ViewN/AView Earnings Details
5/6/2009Q1 2009($10.44)($6.80)ViewN/AView Earnings Details
4/1/2009Q4 2008($6.84)($7.23)ViewN/AView Earnings Details
11/4/2008Q3 2008($11.88)($7.41)ViewN/AView Earnings Details
8/7/2008Q2 2008($15.83)($14.18)ViewN/AView Earnings Details
5/8/2008Q1 2008($10.08)($10.08)ViewN/AView Earnings Details
3/11/2008Q4 2007($8.64)($9.21)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Sunesis Pharmaceuticals (NASDAQ:SNSS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Sunesis Pharmaceuticals (NASDAQ SNSS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.53%
Institutional Ownership Percentage: 51.94%
Insider Trading History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Institutional Ownership by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Sunesis Pharmaceuticals (NASDAQ SNSS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/6/2017Mpm Oncology Impact ManagementMajor ShareholderBuy81,500$2.77$225,755.00View SEC Filing  
11/2/2017Mpm Oncology Impact ManagementMajor ShareholderBuy25,300$2.59$65,527.00View SEC Filing  
10/27/2017Dayton MisfeldtDirectorBuy400,000$2.00$800,000.00View SEC Filing  
12/9/2016Geoffrey M ParkerDirectorBuy3,740$3.87$14,473.8065,151View SEC Filing  
5/26/2016Geoffrey M ParkerDirectorBuy9,500$0.47$4,465.0062,005View SEC Filing  
5/25/2016Geoffrey M ParkerDirectorBuy52,505$0.47$24,677.3530,000View SEC Filing  
12/21/2015Dayton MisfeldtDirectorBuy1,750,000$0.84$1,470,000.00View SEC Filing  
8/25/2015Daniel N Swisher JrCEOBuy12,216$1.01$12,338.16179,510View SEC Filing  
8/24/2015Daniel N Swisher JrCEOBuy12,784$1.01$12,911.84179,510View SEC Filing  
8/29/2014Forest BaskettMajor ShareholderSell266,700$7.97$2,125,599.00View SEC Filing  
8/28/2014Bay City Capital LlcMajor ShareholderSell300,700$7.98$2,399,586.00View SEC Filing  
8/28/2014Dayton MisfeldtDirectorSell200,000$7.89$1,578,000.00View SEC Filing  
8/27/2014Adam R CraigCMOSell2,554$8.00$20,432.00View SEC Filing  
8/27/2014Daniel N Swisher JrCEOSell5,000$8.00$40,000.00View SEC Filing  
8/27/2014Dayton MisfeldtDirectorSell100,700$8.16$821,712.00View SEC Filing  
8/27/2014Eric BjerkholtCFOSell10,000$8.00$80,000.00View SEC Filing  
8/27/2014Krishna Kittu KolluriMajor ShareholderSell108,300$8.17$884,811.00View SEC Filing  
8/12/2014Dayton MisfeldtDirectorSell743,700$6.64$4,938,168.00View SEC Filing  
8/12/2014Equity Opportunities Fu GrowthMajor ShareholderSell710,540$6.63$4,710,880.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sunesis Pharmaceuticals (NASDAQ SNSS) News Headlines

Source:
DateHeadline
Sunesis Pharmaceuticals (SNSS) Given Consensus Rating of "Hold" by AnalystsSunesis Pharmaceuticals (SNSS) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - May 15 at 10:59 AM
Oppenheimer Research Analysts Lift Earnings Estimates for Sunesis Pharmaceuticals (SNSS)Oppenheimer Research Analysts Lift Earnings Estimates for Sunesis Pharmaceuticals (SNSS)
www.americanbankingnews.com - May 11 at 9:38 AM
Sunesis Pharmaceuticals (SNSS) Upgraded to Buy at Zacks Investment ResearchSunesis Pharmaceuticals (SNSS) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - May 10 at 7:05 PM
Analysts Issue Forecasts for Sunesis Pharmaceuticals FY2022 Earnings (SNSS)Analysts Issue Forecasts for Sunesis Pharmaceuticals' FY2022 Earnings (SNSS)
www.americanbankingnews.com - May 10 at 9:36 AM
Edited Transcript of SNSS earnings conference call or presentation 8-May-18 8:30pm GMTEdited Transcript of SNSS earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 8:54 AM
Sunesis Pharmaceuticals (SNSS) Issues  Earnings ResultsSunesis Pharmaceuticals (SNSS) Issues Earnings Results
www.americanbankingnews.com - May 9 at 1:31 PM
Sunesis Pharmaceuticals (SNSS) Management on Q1 2018 Results - Earnings Call TranscriptSunesis Pharmaceuticals' (SNSS) Management on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 8:50 AM
Sunesis Pharmaceuticals (SNSS) "Hold" Rating Reaffirmed at CowenSunesis Pharmaceuticals' (SNSS) "Hold" Rating Reaffirmed at Cowen
www.americanbankingnews.com - May 8 at 9:15 PM
Sunesis Pharmaceuticals beats by $0.06, beats on revenueSunesis Pharmaceuticals beats by $0.06, beats on revenue
seekingalpha.com - May 8 at 5:09 PM
Sunesis Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent HighlightsSunesis Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Highlights
finance.yahoo.com - May 8 at 5:09 PM
Sunesis: 1Q Earnings SnapshotSunesis: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 5:09 PM
Sunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2018 Financial Results and ...Sunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2018 Financial Results and ...
www.nasdaq.com - May 3 at 8:42 AM
Sunesis Pharmaceuticals (SNSS) Stock Rating Upgraded by ValuEngineSunesis Pharmaceuticals (SNSS) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 2 at 6:06 PM
Zacks: Analysts Expect Sunesis Pharmaceuticals (SNSS) to Post -$0.29 EPSZacks: Analysts Expect Sunesis Pharmaceuticals (SNSS) to Post -$0.29 EPS
www.americanbankingnews.com - April 23 at 7:14 PM
Sunesis Pharmaceuticals (SNSS) Receives Average Recommendation of "Hold" from AnalystsSunesis Pharmaceuticals (SNSS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 20 at 8:50 AM
Zacks Investment Research Lowers Sunesis Pharmaceuticals (SNSS) to SellZacks Investment Research Lowers Sunesis Pharmaceuticals (SNSS) to Sell
www.americanbankingnews.com - April 19 at 2:58 PM
Are Options Traders Betting on a Big Move in Sunesis Pharmaceuticals (SNSS) Stock?Are Options Traders Betting on a Big Move in Sunesis Pharmaceuticals (SNSS) Stock?
www.zacks.com - April 9 at 8:56 AM
 Brokerages Expect Sunesis Pharmaceuticals (SNSS) Will Post Earnings of -$0.29 Per Share Brokerages Expect Sunesis Pharmaceuticals (SNSS) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - April 6 at 9:22 PM
Edited Transcript of SNSS earnings conference call or presentation 8-Mar-18 9:30pm GMTEdited Transcript of SNSS earnings conference call or presentation 8-Mar-18 9:30pm GMT
finance.yahoo.com - April 1 at 8:47 AM
Sunesis Pharmaceuticals (SNSS) Presents At Needham And Company 17th Annual Healthcare Conference - SlideshowSunesis Pharmaceuticals (SNSS) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 28 at 4:58 PM
Sunesis Pharmaceuticals (SNSS) Given Consensus Rating of "Hold" by BrokeragesSunesis Pharmaceuticals (SNSS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 26 at 8:04 AM
Sunesis Pharmaceuticals (SNSS) Upgraded to Sell at ValuEngineSunesis Pharmaceuticals (SNSS) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - March 25 at 10:56 AM
Sunesis Pharmaceuticals (SNSS) Expected to Announce Earnings of -$0.29 Per ShareSunesis Pharmaceuticals (SNSS) Expected to Announce Earnings of -$0.29 Per Share
www.americanbankingnews.com - March 20 at 9:08 PM
Sunesis Pharmaceuticals (SNSS) Lowered to Strong Sell at Zacks Investment ResearchSunesis Pharmaceuticals (SNSS) Lowered to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - March 14 at 5:24 PM
Sunesis Pharmaceuticals to Present at Upcoming Investor ConferencesSunesis Pharmaceuticals to Present at Upcoming Investor Conferences
feeds.benzinga.com - March 14 at 4:55 PM
Research Analysts Issue Forecasts for Sunesis Pharmaceuticals, Inc.s FY2018 Earnings (SNSS)Research Analysts Issue Forecasts for Sunesis Pharmaceuticals, Inc.'s FY2018 Earnings (SNSS)
www.americanbankingnews.com - March 14 at 9:50 AM
Sunesis Pharmaceuticals Announces Cancellation of Presentation and Webcast at Cowen & Company 38th Annual ... - GlobeNewswire (press release)Sunesis Pharmaceuticals Announces Cancellation of Presentation and Webcast at Cowen & Company 38th Annual ... - GlobeNewswire (press release)
globenewswire.com - March 14 at 9:20 AM
Sunesis Offers A Great Buying Opportunity After Dip Due To Delay Of Cancer Data - Seeking AlphaSunesis Offers A Great Buying Opportunity After Dip Due To Delay Of Cancer Data - Seeking Alpha
seekingalpha.com - March 14 at 9:20 AM
Sunesis Pharmaceuticals (SNSS) Presents At 38th Annual Cowen And Company Healthcare Conference - SlideshowSunesis Pharmaceuticals (SNSS) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 13 at 6:55 PM
Sunesis Pharmaceuticals Announces Cancellation of Presentation and Webcast at Cowen & Company 38th Annual Health Care ConferenceSunesis Pharmaceuticals Announces Cancellation of Presentation and Webcast at Cowen & Company 38th Annual Health Care Conference
finance.yahoo.com - March 13 at 8:57 AM
Sunesis Pharmaceuticals (SNSS) vs. Prosensa (RNA) Head-To-Head ReviewSunesis Pharmaceuticals (SNSS) vs. Prosensa (RNA) Head-To-Head Review
www.americanbankingnews.com - March 13 at 1:18 AM
Sunesis Pharmaceuticals, Inc. to Post FY2021 Earnings of ($0.42) Per Share, Oppenheimer Forecasts (SNSS)Sunesis Pharmaceuticals, Inc. to Post FY2021 Earnings of ($0.42) Per Share, Oppenheimer Forecasts (SNSS)
www.americanbankingnews.com - March 12 at 9:40 AM
Sunesis Pharmaceuticals (SNSS) Announces Quarterly  Earnings ResultsSunesis Pharmaceuticals (SNSS) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 9 at 6:35 PM
Cantor Fitzgerald Reaffirms "Hold" Rating for Sunesis Pharmaceuticals (SNSS)Cantor Fitzgerald Reaffirms "Hold" Rating for Sunesis Pharmaceuticals (SNSS)
www.americanbankingnews.com - March 9 at 12:10 AM
Sunesis Pharmaceuticals, Inc. to Host Earnings CallSunesis Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - March 8 at 6:08 PM
Sunesis Pharmaceuticals Q4 Earnings PreviewSunesis Pharmaceuticals Q4 Earnings Preview
finance.yahoo.com - March 8 at 6:08 PM
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent HighlightsSunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights
finance.yahoo.com - March 8 at 6:08 PM
Are Earnings Prospects Improving For Loss-Making Sunesis Pharmaceuticals Inc’s (NASDAQ:SNSS)?Are Earnings Prospects Improving For Loss-Making Sunesis Pharmaceuticals Inc’s (NASDAQ:SNSS)?
finance.yahoo.com - March 7 at 8:52 AM
Sunesis Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care ConferenceSunesis Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 8:43 AM
BIO-TECHNE (TECH) vs. Sunesis Pharmaceuticals (SNSS) Critical ComparisonBIO-TECHNE (TECH) vs. Sunesis Pharmaceuticals (SNSS) Critical Comparison
www.americanbankingnews.com - March 5 at 11:36 AM
Sunesis Pharmaceuticals (SNSS) Lowered to Strong Sell at ValuEngineSunesis Pharmaceuticals (SNSS) Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - March 4 at 9:52 AM
-$0.25 EPS Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter-$0.25 EPS Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter
www.americanbankingnews.com - March 3 at 5:24 PM
Sunesis Pharmaceuticals to Host Conference Call on March 8th to Discuss Fourth Quarter and Full-Year 2017 ... - GlobeNewswire (press release)Sunesis Pharmaceuticals to Host Conference Call on March 8th to Discuss Fourth Quarter and Full-Year 2017 ... - GlobeNewswire (press release)
globenewswire.com - March 3 at 8:42 AM
Sunesis Pharmaceuticals, Inc. (SNSS) Given Consensus Recommendation of "Hold" by BrokeragesSunesis Pharmaceuticals, Inc. (SNSS) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 1 at 12:10 PM
Sunesis Pharmaceuticals (SNSS) to Release Quarterly Earnings on WednesdaySunesis Pharmaceuticals (SNSS) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 28 at 1:58 AM
Investors Buy High Volume of Sunesis Pharmaceuticals Call Options (SNSS)Investors Buy High Volume of Sunesis Pharmaceuticals Call Options (SNSS)
www.americanbankingnews.com - February 23 at 8:26 AM
Sunesis Pharmaceuticals (SNSS) Downgraded by Zacks Investment Research to "Sell"Sunesis Pharmaceuticals (SNSS) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - February 15 at 2:08 PM
Sunesis Pharmaceuticals (SNSS) Lowered to Sell at Zacks Investment ResearchSunesis Pharmaceuticals (SNSS) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - February 9 at 2:16 PM
Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of DirectorsSunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors
finance.yahoo.com - February 8 at 8:29 AM
Sunesis Pharmaceuticals, Inc. (SNSS) Given Average Recommendation of "Hold" by AnalystsSunesis Pharmaceuticals, Inc. (SNSS) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 4 at 11:14 AM

SEC Filings

Sunesis Pharmaceuticals (NASDAQ:SNSS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sunesis Pharmaceuticals (NASDAQ:SNSS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sunesis Pharmaceuticals (NASDAQ SNSS) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.